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Abstract
Introduction: Infections in status epilepticus (SE) patients result in severe morbidity making early diagnosis crucial.
As SE may lead to inflammatory reaction, the value of acute phase proteins and white blood cells (WBC) for
diagnosis of infections during SE may be important. We examined the reliability of C-reactive protein (CRP),
procalcitonin (PCT), and WBC for diagnosis of infections during SE.
Methods: All consecutive SE patients treated in the ICU from 2005 to 2009 were included. Clinical and
microbiological records, and measurements of CRP and WBC during SE were analyzed. Subgroup analysis was
performed for additional PCT measurements in the first 48 hours of SE.
Results: A total of 22.5% of 160 consecutive SE patients had infections during SE. Single levels of CRP and WBC
had no association with the presence of infections. Their linear changes over the first three days after SE onset
were significantly associated with the presence of infections (P = 0.0012 for CRP, P = 0.0137 for WBC). Levels of
PCT were available for 31 patients and did not differ significantly in patients with and without infections. Sensitivity
of PCT and CRP was high (94% and 83%) and the negative predictive value of CRP increased over the first three
days to 97%. Specificity was low, without improvement for different cut-offs.
Conclusions: Single levels of CRP and WBC are not reliable for diagnosis of infections during SE, while their linear
changes over time significantly correlate with the presence of infections. In addition, low levels of CRP and PCT
rule out hospital-acquired infections in SE patients.
Introduction
Infection rate of patients with status epilepticus (SE) is
high and associated with increased morbidity, need for
treatment escalation, prolonged hospital stay and addi-
tional resource utilization [1]. SE patients are at risk for
ventilator-associated pneumonia (VAP) due to the need
for mechanical ventilation during their state of altered
consciousness. Therefore, early and accurate diagnosis
of hospital-acquired infections during SE is crucial [1].
Since its identification in 1930, C-reactive protein
(CRP) has been studied as a screening device for inflam-
mation, a marker for disease activity, and as a diagnostic
adjunct [2] as values of CRP may reflect the severity of
inflammation or tissue injury [3,4]. Like many acute
phase proteins, CRP is normally present in trace levels
in serum but increases rapidly and dramatically in
response to a variety of infectious or inflammatory con-
ditions [5]. With the availability of rapid or bedside
tests, determining its diagnostic value is of increasing
importance [6].
Procalcitonin (PCT) is a pre-pro-peptide precursor of
the thyroid hormone calcitonin. Circulating levels of the
PCT can rise several thousand times above normal
under various inflammatory conditions, but most nota-
bly if caused by bacterial infections [7]. Therefore, CRP
and PCT may be promising markers for rapid detection
of infectious complications during SE in the intensive
care unit (ICU).
However, SE itself may lead to systemic inflammatory
reaction with an increase of cytokines in serum during
or immediately after epileptic seizures [8]. Therefore,
epileptic activity may also lead to an increase of CRP,
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of infections and thus reduce the reliability of these bio-
markers for the clinical diagnosis of infectious complica-
tions during SE.
The aim of this study was to examine whether levels
of serum CRP, PCT and WBC are reliable indicators for
the diagnosis of infectious complications during SE.
Material and methods
Setting
This study was performed at the University Hospital
Basel, an 855-bed tertiary care center of Switzerland
with over 30,000 admissions per year. Patients with SE
are treated mainly in the ICU, which has 21 beds. The
local ethical committee EKBB ("Ethikkommission beider
Basel”) approved this study in accordance with the stan-
dards laid down in the 1964 Declaration of Helsinki and
waived the requirement for informed consent (approval
reference number 204/10).
Patients and data collection
Over five consecutive years (1 January 2005 to 31 Decem-
ber 2009), patients hospitalized in the ICU due to SE
confirmed by electroecephalogram (EEG) were selected
from the digital EEG database. EEG recordings were
interpreted by two board certified epileptologists (RS and
SR) who reached a consensus diagnosis after reviews.
CRP and WBC levels were measured daily during the
first three days after SE onset. Values of PCT were
included if measured during the first 48 hours of SE.
A comprehensive review of medical records and clini-
cal data was performed by a board certified neurologist
(RS) and by an infectious disease specialist (ST-S). Data
collection included gender, age, all medical diagnoses,
duration and type of SE, length of hospital and ICU
stay. These data were collected in order to establish a
cohort for ongoing analysis regarding the diagnostic
value of biomarkers for infectious complications and
their correlation with course and outcome of SE.
Definitions and treatment of status epilepticus
Status epilepticus was defined according to published
recommendations [9], as seizure activity, lasting longer
than five minutes or recurrent seizure activity lasting
more than five minutes without the patient regaining
consciousness. Clinically suspected seizure activity was
confirmed by EEG. SE episodes were categorized as con-
vulsive (CSE), subtle (SSE), and nonconvulsive status
epilepticus (NCSE). The diagnosis of CSE was made if
recurrent convulsions were present without complete
recovery between seizures. The diagnoses of CSE and
SSE were made, as defined by Treiman et al. [10]. For
the diagnosis of SSE, seizure activity on EEG had to
endure when the associated motor responses were
fragmentary or partially absent. For the diagnosis of
NCSE, at least one of the three primary criteria and one
of the four secondary criteria as defined by Young et al.
had to be fulfilled [11]. SE duration was defined as the
period from the time of diagnosis to the time of cessa-
tion of clinical manifestations and first EEG without epi-
leptic activity.
Refractory SE (RSE) was defined as SE without recov-
ery after the application of i.v. benzodiazepines and one
further i.v. antiepileptic drug, such as phenytoin, val-
proic acid, a combination of both or levetiracetam.
Treatment of SE was standardized according to the
guidelines of the Swiss Status Epilepticus Consensus
Conference from 2005 [12,13].
Definitions/criteria of infections
A protocol for monitoring infections was established for
all patients on the ICU. It included drawing of blood
cultures, urine cultures, cultures from tracheal aspirates
or sputum, and performance of a chest x-ray in any
patient with new onset of fever or hypothermia. If there
were other foci suspected to be the origin of an infec-
tion, these were sampled accordingly (for example, cere-
brospinal fluid (CSF) cultures, swabs of wounds,
cultures of biopsies).
All infections that occurred and were diagnosed 14
days before or during SE were assessed. Patients were
categorized into three groups: (1) patients with infections
before SE, (2) patients with infections during SE, and (3)
patients without infections. Therefore, clinical courses
and primary sites of infection were evaluated according
to information supplied by the laboratory, clinical and
radiological results in the medical records (that is, body
temperature, WBC levels, blood cultures, urine cultures,
cultures from CSF, cultures from transtracheal aspirates
or sputum, antibody titer levels, histopathological results
and reports from radiological findings) and from written
statements from the primary caring physicians (that is, all
written statements relating to clinical signs of possible
infections). Furthermore, all microbiological data were
obtained during hospitalization and retrospectively cross-
checked by a board certified infectious disease specialist
(ST-S) by using the computerized database of the infec-
tion control microbiology surveillance. Only infections
that met the criteria according to the Center for Disease
Control (CDC) in the retrospective survey were accepted
as infections [14] (Table 1). As the sensitivity of clinical
suspicion of VAP is often too high, we applied the criteria
of the American Thoracic Society and the Infectious Dis-
eases Society of America [15].
Patients with infections diagnosed more than 14 days
before SE onset were excluded from further analyzes of
sensitivity and specificity of CRP and WBC for detection
of infections during SE.
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Page 2 of 10Table 1 Identified infections and the applied CDC definitions according to Garner et al. [14]
Respiratory tract infections
(n = 47; 29.4% of all patients)
RTI must meet one of the following criteria:
1. Rales or dullness to percussion on physical examination of chest AND any of the following:
a. New onset of purulent sputum or change in character of sputum
b. Organism isolated from blood culture
c. Isolation of pathogen from specimen obtained by transtracheal aspirate, bronchial brushing, or
biopsy
2. Chest radiographic examination shows new or progressive infiltrate, consolidation, cavitation, or
pleural effusion AND any of the following:
a. New onset of purulent sputum or change in character of sputum
b. Organism isolated from blood culture
c. Isolation of pathogen from specimen obtained by transtracheal aspirate, bronchial brushing, or
biopsy
d. Isolation of virus or detection of viral antigen in respiratory secretions
e. Diagnostic single antibody titer (IgM) or fourfold increase in paired serum samples (IgG) for
pathogen
f. Histopathologic evidence of pneumonia
Bloodstream infections
(includes laboratory-confirmed bloodstream
infection and clinical sepsis)
(n = 12; 7.5% of all patients)
In our study we did not differ between primary and secondary bloodstream infections
Primary bloodstream infections:
Laboratory-confirmed bloodstream infection must meet one of the following criteria:
1. Recognized pathogen isolated from blood culture AND pathogen is not related to infection at
another site
2. One of the following: fever (>38°C), chills, or hypotension AND any of the following:
a. Common skin contaminant isolated from two blood cultures drawn on separate occasions AND
organism is not related to infection at another site; b. Common skin contaminant isolated from
blood culture from patient with intravascular access device AND physician institutes appropriate
antimicrobial therapy; c. Positive antigen test on blood AND organism is not related to infection at
another site
Secondary bloodstream infections:
When an organism isolated from blood culture is compatible with a related nosocomial infection
at another site, the bloodstream infection is classified as a secondary bloodstream infection.
Exceptions to this are intravascular device-associated bloodstream infections, all of which are
classified as primary
even if localized signs of infection are present at the access site.
Symptomatic urinary tract infection
(n = 6; 3.8% of all patients)
Symptomatic urinary tract infection must meet one of the following criteria:
1. One of the following: fever (>38°C), urgency, frequency, dysuria, or suprapubic tenderness AND
a urine culture of > = 10^5 colonies/ml urine with no more than two species of organisms
2. Two of the following: fever (>38°C), urgency, frequency, dysuria, or suprapubic tenderness AND
any of the following:
a. Dipstick test positive for leukocyte esterase and/or nitrate
b. Pyuria (310 white blood cells [WBC]/ml^3 or WBC/high-power field of unspun urine)
c. Organisms seen on Gram stain of unspun urine
d. Two urine cultures with repeated isolation of the same uropathogen with > = 10^2 colonies/ml
urine in nonvoided specimens
e. Urine culture with < = 10^5 colonies/ml urine of single uropathogen in patient being treated
with appropriate antimicrobial therapy
f. Physician’s diagnosis
g. Physician institutes appropriate antimicrobial therapy
Encephalitis
(n = 5; 3.1% of all patients)
Encephalitis must meet one of the criteria:
1. Organism isolated from culture of brain tissue or dura
2. Two of the following with no other recognized cause: headache, dizziness, fever (>38°C),
localizing neurologic signs, changing level of consciousness, or confusion, AND physician institutes
appropriate antimicrobial therapy if diagnosis is made ante mortern AND any of the following:
a. Organism seen on microscopic examination of brain or abscess tissue obtained by needle
aspiration or by biopsy during surgery or autopsy
b. Positive antigen test on blood or urine
c. Radiographic evidence of infection
d. Diagnostic single antibody titer (IgM) or fourfold increase in paired serum samples (IgG) for
pathogen
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CRP concentrations were determined by an enzyme
immunoassay with a detection limit of 0.5 mg/L (EMIT;
Merck Diagnostica, Zürich, Switzerland). PCT was mea-
sured with a high sensitive time-resolved amplified cryp-
tate emission (TRACE) technology assay (PCT
Kryptor
®, B.R.A.H.M.S. AG, Hennigsdorf, Germany).
The assay has a detection limit of 0.02 μg/L and func-
tional assay sensitivity of 0.06 μg/L, that is, 3- to 10-fold
above normal mean values. Analyses for different cut-off
values, including the threshold of 0.1 ug/L, as recom-
mended by the manufacturer, were performed.
Statistical analysis
Descriptive analyses for sociodemographic factors, bio-
markers of infection, comorbidities and outcomes were
performed. Categorical variables were summarized as
counts and proportions and continuous variables as
means and standard deviations. Logistic regressions
were used to determine the associations between the
categories “infections” and “respiratory tract infections”
(RTI), as the largest subgroups of infections, and the dif-
ferent comorbidities. To analyze the diagnostic accuracy
of CRP and WBC levels for detection of infections dur-
ing SE, all patients with infections before SE and with-
out infections were excluded. When comparing means
for two different groups, the Mann-Whitney U-test was
used. When comparing more than two groups the Kruk-
sal-Wallis test was applied. Sensitivity and specificity, as
well as positive and negative predictive values, were cal-
culated for CRP and WBC, for each of the first three
days after SE onset, respectively, using the recom-
mended cut-offs as described above. CRP levels ≤10 mg/
L were considered normal, levels greater than 10 mg/L
were interpreted as elevated according to the manufac-
turer’s recommendations. Cut-off levels of 10.0 × 10
9/L
were used for WBC. To have an indicator of the change
of the different biomarkers with time, this change was
calculated for each patient first. This was done by
means of a linear regression on the values of CRP and
WBC for the three different days of measurements (a
linear relationship of CRP and WBC levels with time
was assumed). Then logistic regressions or general linear
models were used to determine the relationship between
the presence of infections during SE and the CRP’sa n d
WBC’s change with time. To find cut-off points on the
level of PCT, which would indicate an infection, receiver
operating characteristic (ROC) curves were used and
sensitivity and specificity for different cut-off points
were calculated. Statistical analysis was performed with
SAS version 9.2 (SAS Institute 2002, Cary, NC, USA).
Results
A total of 160 consecutive patients with SE were identi-
fied during five consecutive years in the University Hos-
pital of Basel. The algorithm of patients’ in- and
exclusion is presented in the flow-chart (Figure 1).
Median age was 65 years (range 17 to 91 years) (Table 2)
and cardiopathy and metabolic disorders were the most
commonly encountered underlying diseases (55, 34.4%
and 46, 28.7%, respectively). Only 29 (18.1%) patients were
diagnosed with epilepsy prior to the current episode of SE.
The majority of patients suffered from NCSE (72, 45.0%)
and nearly one-third had a refractory course of SE (52,
32.5%). Median length of SE was three days (SD ± 5.3).
Forty-one (25.6%) patients died. Further baseline charac-
teristics and clinical features are summarized in Table 2.
In total, 57 (35.6%) patients had infections before or dur-
ing SE. Table 1 shows all diagnosed infections and the
applied CDC criteria. Thirty-six (22.5%) infections were
diagnosed during and 21 (13%) before SE. The majority of
infections diagnosed during SE (34/57; 59.7% of all infec-
tions) were respiratory tract infections (RTI), more than a
third of all RTIs were VAPs (12/34; 35.3% of all RTI dur-
ing SE and 13.6% of ventilated patients). Relevant patho-
gens could be detected in most cases of RTI (28/34;
82.4%), and included Staphylococcus aureus, Streptococci
and gram-negativ bacteria as Haemophilus spp., Escheri-
chia coli, Serratia spp. Enterobacter spp.a n dPseudomonas
aeruginosa. In the remaining, diagnosis was established
due to clinical findings as new onset of purulent sputum
and new or progressive infiltrates in the chest x-ray
Table 1 Identified infections and the applied CDC definitions according to Garner et al. [14] (Continued)
Meningitis
(n = 1; 0.6% of all patients)
Meningitis must meet one of the following criteria:
1. Organism isolated from culture of cerebrospinal fluid (CSF)
2. One of the following with no other recognized cause: fever (>38°C), headache, stiff neck,
meningeal signs, cranial nerve signs, or irritability, AND physician institutes appropriate
antimicrobial therapy if diagnosis is made ante mortem AND any of the following:
a. Increased white cells, elevated protein, and/or decreased glucose in CSF
b. Organisms seen on Gram stain of CSF
c. Organism isolated from blood culture
d. Positive antigen test on CSF, blood, or urine
e. Diagnostic single antibody titer (IgM) or fourfold increase in paired serum samples (IgG) for
pathogen
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tions [14] and the criteria of the American Thoracic
Society and the Infectious Diseases Society of America
[15].
To analyze the diagnostic accuracy of CRP and WBC
levels for detection of infections during SE, 21 patients
with infections before SE were excluded, as already ele-
vated CRP and WBC levels due to prior infection can
reduce prognostic value. A total of 139 patients
remained for further analyses, of which 36 (27%) had
infections during SE. Sensitivity and specificity, as well
as positive and negative predictive values of WBC, were
low (Table 3). Sensitivity and the negative predictive
value of CRP steadily increased from day 1 to day 3 of
SE ranging from 70.0% to 93.3% and 85.9% to 96.9%,
respectively; however, specificity and positive predictive
value remained low (28.9% to 60.2%) (Table 2).
Analysis of the linear change with time from day 1 to
day 3 for CRP and WBC levels and its association with
infections during SE was performed for all 160 patients
(comparing results for patients with infections during
SE and without infections) and was found to be highly
significant for both markers (Table 3). For each 1 mg/L
of CRP the linear time change from the first day to the
third day after onset of SE was significantly associated
with the presence of infections during SE (OR 1.018, CI
1.007 to 1.029, P = 0.0012). The change of WBC counts,
expressed in 10
9/L, in the same time period was also
associated with the presence of infections during SE
(OR 0.754, CI 0.603 to 0.944, P = 0.0137).
PCT was measured in 31 (19.4%) patients during the first
48 hours of SE. Eighteen of these patients had infections
during SE. In all 13 patients without infections, PCT levels
were higher than 0.1 μg/L, the recommended threshold
value set by the manufacturer (Table 2). Mean PCT level in
the entire study group was 2 μg/L (± 6). No significant dif-
ferences could be detected between PCT levels of patients
with infections during SE (mean level 2.92 μg/L ± 7.8) and
without infections (mean level 0.73 μg/L ± 0.89) (P = 0.15).
Regarding the recommended cut-off value of 0.1 μg/L, sen-
sitivity of PCT to detect infections during SE was high
(94.4%) with a negative predictive value of 66.7%. However,
specificity was low (15.4%) with a positive predictive value
of 60.7%. As there are studies that have used higher cut-off
values between 0.25 and 0.5 ug/L to withhold antibiotics in
patients, that is, considered not to have an infection
[16,17], different cut-off values for PCT were analyzed in
addition without further improvement of sensitivity and
specificity (Figure 2). At the maximum, Youden’si n d e x
(0.4145) sensitivity was 72.2% and specificity 69.2% at a
c u t - o f fo f0 . 5 8μg/L (Figure 2). Baseline characteristics,
including age, gender and number of comorbidities, did
not differ significantly between the 13 patients with infec-
tions during SE and the 18 patients without infections.
Discussion
To our knowledge, this is the first study to examine the
reliability of CRP, WBC and PCT for the diagnosis of
infections in patients with SE. Of note, the knowledge
about systemic inflammatory reactions with elevated
Figure 1 Flow-chart. SE = status epilepticus; PCT = procalcitonin.
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accelerating the uncertainty for the clinicians about the
use of acute phase proteins for the diagnosis of infec-
tions in SE. Numerous studies have identified different
cut-off levels for CRP, PCT and WBC for the presence
of infections in ICU patients but a consensus was not
found [6,23-29].
In our study, CRP demonstrated a high negative pre-
dictive value for infections in patients with SE. In addi-
tion, its sensitivity steadily increased from Day 1 to Day
3 of SE. However, specificity and positive predictive
value were low, making it a poor predictor for the pre-
sence of infections during SE. However, the cut-off cho-
sen for CRP (<10 mg/L) is low and might have led to
high sensitivity and low specificity. Single values of
WBC counts were insufficient to either rule in or rule
out the presence of infections during SE. ROC curves
were not performed, as linear changes of CRP and WBC
levels over time were highly significant with the pre-
sence of infections and, as mentioned above, many pre-
vious studies have found numerous cut-off values by
focusing on infection in ICU patients, making it com-
plex and obscure for the clinicians to rely on multiple
recommendations. Therefore, we have focused on the
change of biomarker levels over time. In our study
population, the linear changes with time for both CRP
and WBC levels were significantly associated with the
diagnosis of infections, suggesting that both parameters
are useful when evaluating their time course rather than
single values. For the presented odds ratios, it has to be
taken into account that they are given for each change
of 1 mg/L of CRP and 10
9/L for WBC, respectively.
This finding might be reflected by the increasing specifi-
city on day 3 of SE in comparison to day 1.
The diagnostic accuracy of PCT could only be analyzed
in a small proportion of our patients and only as single
measurements. Data for analysis of linear change with
time were insufficient. Regarding the recommended cut-
off value of 0.1 μg/L, sensitivity of PCT to detect infections
was high; however, specificity was low. We conducted
further statistical analysis to determine if different cut-off
values could improve its performance, however, without
relevant success. In a recent study, the diagnostic value of
PCT for diagnosis of nosocomial pneumonia has also been
questioned [25]. When examining 104 consecutive ICU
patients, diagnostic sensitivity and specificity for nosoco-
mial pneumonia was 50.0% and 48.6%, respectively. Of
interest, performance of PCT regarding sensitivity was
much better in our study at the maximum Youden’s index
of 0.4145 with a sensitivity of 72.2% and specificity of
Table 2 Basic demographics and clinical features (n =
160)
Sociodemographic
Gender n %
Female 88 55.0
Male 72 45.0
Age years SD or range
Mean 62.8 ±16.9
Median 65.0 17 - 91
Clinical features
SE types n %
CSE 42 26.3
SSE 46 28.7
NCSE 72 45.0
Comorbidities n %
Cardiopathy 55 34.4
Metabolic disorder 46 28.8
Known epilepsy 29 18.1
Tumor (in the CNS) 20 12.5
Tumor (outside the CNS) 17 10.6
Neurodegenerative disease 11 6.9
Acute stroke 9 5.6
Traumatic brain injury 8 5.0
Autoimmune disease 8 5.0
Intracerebral hemorrhage 5 3.1
Subdural hemorrhage 4 2.5
Subarachnoideal hemorrhage 3 1.9
Arteriovenous malformation 2 1.3
Infections of all SE patients n %
Patients with infections in total 57 35.6
Patients with infections before SE 21 13.1
Patients with infections during SE 36 22.5
Course days SD or range
Length of SE mean 3.0 ±5.3
median 1.0 0 - 43
Length of ICU stay mean 7.9 ±9.1
median 4.0 0 - 57
Length of hospital stay mean 20.5 ±16.7
median 17.0 1 - 102
Length of intubation mean 7.6 ±10.1
median 4.0 0 - 65
Cardiopulmonary resuscitation n, % 25 15.6
RSE n, % 52 32.5
Outcome n %
Back home 29 18.1
Rehabilitation 47 29.4
Other hospital 32 20.0
Nursing home 10 6.3
Death 41 25.6
Missing data 1 0.6
SD = standard deviation; SE = status epilepticus; CSE = convulsive status
epilepticus; SSE = subtle
status epilepticus; NCSE = nonconvulsive status epilepticus; RSE = refractory
status epilepticus;
CPR = cardiopulmonary resuscitation; CNS = central nervous system; CRP = C-
reactive protein; WBC
= white blood cells; ICU = intensive care unit
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study of 70 patients, PCT analysis for suspected nosoco-
mial infections in ICU patients revealed similar results
with a cut-off value for PCT of 0.44 μg/L and a sensitivity
of 65.2% and a specificity of 83.0% [24]. The authors also
reported poor predictive value of CRP and WBC for detec-
tion of hospital-acquired infections. As mean levels of
CRP, WBC and PCT were elevated in patients with and
without infections during SE and no significant differences
in the PCT levels, which is regarded as the most sensitive
biomarker for detection of bacterial infections, could be
detected in this study, our data suggest that epileptic activ-
ity itself may raise serum PCT, CRP and WBC levels. This
finding underlines the hypothesis that SE itself could
cause a systemic inflammatory reaction - an assumption
also reported in the literature by detection of significantly
higher levels of cytokines, especially interleukin-6, in the
blood of patients with SE [8]. Cytokines are known to
influence acute phase protein production, with interleu-
kin-6 being a major inducer [30]. The role of inflammation
in maintaining an epileptic state needs further investiga-
tion as it could imply new treatment options for this
severe and often fatal disease.
A further explanation for elevated biomarker levels
without evidence of infections during SE might be the
presence of comorbidities in this cohort. Patients with
cardiopulmonary resuscitation and cerebral hypoxia
have shown PCT elevation in the absence of infections
[31] and also multiple trauma with or without brain
injury, as present in our study, were shown to be asso-
ciated with an increase of PCT concentrations without
infectious complications [32]. However, there were no
significant differences of comorbidities between patients
with and without infections and also no differences
between patients with and without RTI, the largest sub-
group of infections in this study (Table 4). We did not
perform analyzes for the subgroup with autoimmune
diseases, as this group had a small size of only 5% of the
cohort. Moreover, we cannot exclude that there were
some cases where infections were present but could not
be detected.
The authors are well aware of limitations of this study:
the retrospective character and the small patient sample.
Nevertheless, as CRP and WBC are measured routinely
and daily in every patient on the ICU in clinical practice, a
selection bias appears very unlikely. Furthermore, the
selection of patients in dependence of performed PCT
measurements is an obvious selection bias. The lack of a
biomarker-specific time course for PCT in this cohort as
well as the smaller sample size does not allow a direct
head-to-head comparison to the other markers and may
also weaken its prognostic strength for infections, which
should be analyzed in further prospective studies. Inter-
rater agreement calculation was not performed in this
study. However, all EEG reports were based on EEG inter-
pretation by two board certified epileptologists and
Table 3 Validation of C-reactive protein levels and white blood cell counts for infectious complications during SE
CRP levels
(mg/L)
Infections
during SE (n = 36)
No infections(n = 103) Sensitivity Specificity PPV NPV LR+ LR-
SD or range SD or range
CRP on day 1 of SE mean 40.80 44.54 32.35 50.09 70.0% 53.4% 30.4% 85.9% 1.5 1.8
median 28.35 0.6 - 178.8 7.60 0.3 - 225.5
CRP on day 2 of SE mean 77.17 70.13 42.90 53.54 86.7% 37.9% 28.9% 90.7% 1.4 0.4
median 55.20 0.6 - 245.0 22.00 0.5 - 233.5
CRP on day 3 of SE mean 116.04 98.01 62.39 67.99 93.3% 60.2% 40.6% 96.9% 2.3 0.1
median 92.35 1.0 - 383.8 36.95 1.2 - 256.7
White blood cell levels
(x10
9/L)
Infections
during SE (n = 36)
No infections
(n = 103)
Sensitivity Specificity PPV NPV LR+ LR-
SD or range SD or range
WBC on day 1 of SE mean 12.23 6.44 10.71 5.05 72.5% 51.5% 36.7% 82.8% 1.5 0.5
median 10.50 2.8 - 26.4 10.00 1.2 - 32.7
WBC on day 2 of SE mean 9.75 5.09 10.62 5.68 36.7% 55.3% 19.3% 75.0% 0.8 1.1
median 9.45 1.6 - 29.7 9.80 1.0 - 34.4
WBC on day 3 of SE mean 9.52 5.00 9.64 4.64 33.3% 63.1% 20.8% 76.5% 0.9 1.1
median 8.85 3.0 - 26.0 8.40 0.8 - 23.3
Association with infections during SE (Infections during SE vs. no infections during SE) (n = 160)
Marker Linear change with time OR* 95% CI p-value
CRP over time Change from day 1 to 3 (mg/L) 1.018 1.007-1.029 0.0012
WBC over time Change from day 1 to 3 (x10
9/L) 0.754 0.603-0.944 0.0137
SD = standard deviation; SE = status epilepticus; CPR = cardiopulmonary resuscitation; CNS = central nervous system; CRP = C-reactive protein; WBC = white
blood cells; PPV = positive predictive value; NPV = negative predictive value; LR+ = likelihood ratio positive; LR- = likelihood ratio negative
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addition, all microbiological data that were obtained dur-
ing hospitalization were retrospectively, independently
cross-checked by a board certified infectious disease
specialist using the computerized database of the infection
control microbiology surveillance and only if the required
definitions by the CDC were fulfilled, was the diagnosis of
infection accepted.
Figure 2 Receiver Operating Characteristic for procalcitonin levels and development of infections before or during status epilepticus.
PCT = procalcitonin; SE = status epilepticus.
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Page 8 of 10Conclusions
Single levels of CRP and WBC are not reliable for diag-
nosis of infections during SE, while linear changes of
CRP levels and WBC counts over time are significantly
correlated with the presence of infections during SE. In
addition, normal levels of CRP and PCT rule out hospi-
tal-acquired infections in SE patients. Further studies
will be needed to elucidate whether changes in PCT
levels over time would be an even more accurate
approach for diagnosis of infections during SE.
Key messages
￿ Single levels of CRP and WBC are not reliable for
diagnosis of infections during SE, possibly due to a sys-
temic inflammatory reaction caused by SE itself.
￿ Linear changes of CRP levels and WBC counts sig-
nificantly correlate with the presence of infectious com-
plications during SE.
￿ Low levels of CRP and PCT rule out hospital-
acquired infections in SE patients.
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